|
1
|
DiNardo CD, Erba HP, Freeman SD and Wei
AH: Acute myeloid leukaemia. Lancet. 401:2073–2086. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrara F: Unanswered questions in acute
myeloid leukaemia. Lancet Oncol. 5:443–450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papaemmanuil E, Gerstung M, Bullinger L,
Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F,
Bolli N, et al: Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shallis RM, Wang R, Davidoff A, Ma X and
Zeidan AM: Epidemiology of acute myeloid leukemia: Recent progress
and enduring challenges. Blood Rev. 36:70–87. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khoury JD, Solary E, Abla O, Akkari Y,
Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et
al: The 5th edition of the world health organization classification
of haematolymphoid tumours: Myeloid and histiocytic/dendritic
neoplasms. Leukemia. 36:1703–1719. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Chu X, Wang J, An L, Liu Y, Li L
and Xu J: Clinical characteristics and optimal therapy of acute
myeloid leukemia with myelodysplasia-related changes: A
retrospective analysis of a cohort of Chinese patients. Turk J
Haematol. 38:188–194. 2021.PubMed/NCBI
|
|
8
|
Sengsayadeth S, Gatwood KS, Boumendil A,
Labopin M, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D,
Niederwieser D, et al: Conditioning intensity in secondary AML with
prior myelodysplastic syndrome/myeloproliferative disorders: An
EBMT ALWP study. Blood Adv. 2:2127–2135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boddu P, Kantarjian HM, Garcia-Manero G,
Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M,
Bhalla KN, Daver N, et al: Treated secondary acute myeloid
leukemia: A distinct high-risk subset of AML with adverse
prognosis. Blood Adv. 1:1312–1323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amaki K: French-American-British (FAB)
classification of acute leukemia. Rinsho Ketsueki. 23:988–990.
1982.(In Japanese). PubMed/NCBI
|
|
11
|
Vardiman JW, Harris NL and Brunning RD:
The World Health Organization (WHO) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lindsley RC, Mar BG, Mazzola E, Grauman
PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP,
et al: Acute myeloid leukemia ontogeny is defined by distinct
somatic mutations. Blood. 125:1367–1376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duncavage EJ, Bagg A, Hasserjian RP,
DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L,
Vannucchi AM, Patel KP, et al: Genomic profiling for clinical
decision making in myeloid neoplasms and acute leukemia. Blood.
140:2228–2247. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Kao YR, Sun D, Todorova TI,
Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A and Steidl
U: Myelodysplastic syndrome progression to acute myeloid leukemia
at the stem cell level. Nat Med. 25:103–110. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dillon LW, Ghannam J, Nosiri C, Gui G,
Goswami M, Calvo KR, Lindblad KE, Oetjen KA, Wilkerson MD, Soltis
AR, et al: Personalized single-cell proteogenomics to distinguish
acute myeloid leukemia from non-malignant clonal hematopoiesis.
Blood Cancer Discov. 2:319–325. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Østgård LS, Medeiros BC, Sengeløv H,
Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher
CW, Preiss B, et al: Epidemiology and clinical significance of
secondary and therapy-related acute myeloid leukemia: A national
population-based cohort study. J Clin Oncol. 33:3641–3649. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao Y, Jia M, Mao Y, Cai H, Jiang X, Cao
X, Zhou D and Li J: Distinct mutation landscapes between acute
myeloid leukemia with myelodysplasia-related changes and de novo
acute myeloid leukemia. Am J Clin Pathol. 157:691–700. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang H, He R, Chiu A, Viswanatha DS,
Ketterling RP, Patnaik MS and Reichard KK: Genetic factors in acute
myeloid leukemia with myelodysplasia-related changes. Am J Clin
Pathol. 153:656–663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chinese Society of Hematology and Chinese
Medical Association, . Chinese guidelines for diagnosis and
treatment of myelodysplastic syndromes (2019). Zhonghua Xue Ye Xue
Za Zhi. 40:89–97. 2019.(In Chinese). PubMed/NCBI
|
|
22
|
Hellström-Lindberg E, Tobiasson M and
Greenberg P: Myelodysplastic syndromes: Moving towards personalized
management. Haematologica. 105:1765–1779. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Woods BA and Levine RL: The role of
mutations in epigenetic regulators in myeloid malignancies. Immunol
Rev. 263:22–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamashita M, Dellorusso PV, Olson OC and
Passegué E: Dysregulated haematopoietic stem cell behaviour in
myeloid leukaemogenesis. Nat Rev Cancer. 20:365–382. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mishra SK, Millman SE and Zhang L:
Metabolism in acute myeloid leukemia: Mechanistic insights and
therapeutic targets. Blood. 141:1119–1135. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Montalban-Bravo G, Kanagal-Shamanna R,
Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K,
Short NJ, DiNardo CD, et al: Outcomes of acute myeloid leukemia
with myelodysplasia related changes depend on diagnostic criteria
and therapy. Am J Hematol. 95:612–622. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haase D, Germing U, Schanz J, Pfeilstöcker
M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R,
Giagounidis AA, et al: New insights into the prognostic impact of
the karyotype in MDS and correlation with subtypes: Evidence from a
core dataset of 2124 patients. Blood. 110:4385–4395. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jädersten M, Saft L, Smith A,
Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R,
Schlegelberger B, Porwit A, et al: TP53 mutations in low-risk
myelodysplastic syndromes with del(5q) predict disease progression.
J Clin Oncol. 29:1971–1979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pitel BA, Sharma N, Zepeda-Mendoza C,
Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z,
Kanagal-Shamanna R, Viswanatha D, et al: Myeloid malignancies with
5q and 7q deletions are associated with extreme genomic complexity,
biallelic TP53 variants, and very poor prognosis. Blood Cancer J.
11:182021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cordoba I, González-Porras JR, Nomdedeu B,
Luño E, de Paz R, Such E, Tormo M, Vallespi T, Collado R, Xicoy B,
et al: Better prognosis for patients with del(7q) than for patients
with monosomy 7 in myelodysplastic syndrome. Cancer. 118:127–133.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Inaba T, Honda H and Matsui H: The enigma
of monosomy 7. Blood. 131:2891–2898. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nagamachi A, Matsui H, Asou H, Ozaki Y,
Aki D, Kanai A, Takubo K, Suda T, Nakamura T, Wolff L, et al:
Haploinsufficiency of SAMD9L, an endosome fusion facilitator,
causes myeloid malignancies in mice mimicking human diseases with
monosomy 7. Cancer Cell. 24:305–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wong CC, Martincorena I, Rust AG, Rashid
M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C; Chronic Myeloid
Disorders Working Group of the International Cancer Genome
Consortium; Green AR, ; et al: Inactivating CUX1 mutations promote
tumorigenesis. Nat Genet. 46:33–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bejar R, Stevenson KE, Caughey B, Lindsley
RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, et
al: Somatic mutations predict poor outcome in patients with
myelodysplastic syndrome after hematopoietic stem-cell
transplantation. J Clin Oncol. 32:2691–2698. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lindsley RC, Saber W, Mar BG, Redd R, Wang
T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, et al:
Prognostic mutations in myelodysplastic syndrome after stem-cell
transplantation. N Engl J Med. 376:536–547. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haase D, Stevenson KE, Neuberg D,
Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G,
Haferlach C, Haferlach T, et al: TP53 mutation status divides
myelodysplastic syndromes with complex karyotypes into distinct
prognostic subgroups. Leukemia. 33:1747–1758. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Levine AJ and Oren M: The first 30 years
of p53: Growing ever more complex. Nat Rev Cancer. 9:749–758. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aubrey BJ, Kelly GL, Janic A, Herold MJ
and Strasser A: How does p53 induce apoptosis and how does this
relate to p53-mediated tumour suppression? Cell Death Differ.
25:104–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bernard E, Nannya Y, Hasserjian RP, Devlin
SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki
R, Malcovati L, et al: Implications of TP53 allelic state for
genome stability, clinical presentation and outcomes in
myelodysplastic syndromes. Nat Med. 26:1549–1556. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bernard E, Nannya Y, Yoshizato T,
Hasserjian RP, Saiki R, Shiozawa Y, Devlin SM, Tuechler H, Sarian
A, Malcovati L, et al: TP53 state dictates genome stability,
clinical presentation and outcomes in myelodysplastic syndromes.
Blood. 134:6752019. View Article : Google Scholar
|
|
41
|
Yu J, Du Y, Jalil A, Ahmed Z, Mori S,
Patel R, Varela JC and Chang CC: Mutational profiling of myeloid
neoplasms associated genes may aid the diagnosis of acute myeloid
leukemia with myelodysplasia-related changes. Leuk Res.
110:1067012021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao D, Eladl E, Zarif M, Capo-Chichi JM,
Schuh A, Atenafu E, Minden M and Chang H: Molecular
characterization of AML-MRC reveals TP53 mutation as an adverse
prognostic factor irrespective of MRC-defining criteria, TP53
allelic state, or TP53 variant allele frequency. Cancer Med.
12:6511–6522. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gelsi-Boyer V, Brecqueville M, Devillier
R, Murati A, Mozziconacci MJ and Birnbaum D: Mutations in ASXL1 are
associated with poor prognosis across the spectrum of malignant
myeloid diseases. J Hematol Oncol. 5:122012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thol F, Friesen I, Damm F, Yun H,
Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A,
Wichmann M, et al: Prognostic significance of ASXL1 mutations in
patients with myelodysplastic syndromes. J Clin Oncol.
29:2499–2506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Inoue D, Kitaura J, Matsui H, Hou HA, Chou
WC, Nagamachi A, Kawabata KC, Togami K, Nagase R, Horikawa S, et
al: SETBP1 mutations drive leukemic transformation in ASXL1-mutated
MDS. Leukemia. 29:847–857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Prats-Martín C, Burillo-Sanz S,
Morales-Camacho RM, Pérez-López O, Suito M, Vargas MT,
Caballero-Velázquez T, Carrillo-Cruz E, González J, Bernal R and
Pérez-Simón JA: ASXL1 mutation as a surrogate marker in acute
myeloid leukemia with myelodysplasia-related changes and normal
karyotype. Cancer Med. 9:3637–3646. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abrahamsson AE, Geron I, Gotlib J, Dao KH,
Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M,
et al: Glycogen synthase kinase 3beta missplicing contributes to
leukemia stem cell generation. Proc Natl Acad Sci USA.
106:3925–3929. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ichikawa M, Yoshimi A, Nakagawa M,
Nishimoto N, Watanabe-Okochi N and Kurokawa M: A role for RUNX1 in
hematopoiesis and myeloid leukemia. Int J Hematol. 97:726–734.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen CY, Lin LI, Tang JL, Ko BS, Tsay W,
Chou WC, Yao M, Wu SJ, Tseng MH and Tien HF: RUNX1 gene mutation in
primary myelodysplastic syndrome-the mutation can be detected early
at diagnosis or acquired during disease progression and is
associated with poor outcome. Br J Haematol. 139:405–414. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang K, Zhou F, Cai X, Chao H, Zhang R and
Chen S: Mutational landscape of patients with acute myeloid
leukemia or myelodysplastic syndromes in the context of RUNX1
mutation. Hematology. 25:211–218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kaisrlikova M, Vesela J, Kundrat D,
Votavova H, Merkerova MD, Krejcik Z, Divoky V, Jedlicka M, Fric J,
Klema J, et al: RUNX1 mutations contribute to the progression of
MDS due to disruption of antitumor cellular defense: A study on
patients with lower-risk MDS. Leukemia. 36:1898–1906. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Song WJ, Sullivan MG, Legare RD, Hutchings
S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, et
al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia
with propensity to develop acute myelogenous leukaemia. Nat Genet.
23:166–175. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tsai SC, Shih LY, Liang ST, Huang YJ, Kuo
MC, Huang CF, Shih YS, Lin TH, Chiu MC and Liang DC: Biological
activities of RUNX1 mutants predict secondary acute leukemia
transformation from chronic myelomonocytic leukemia and
myelodysplastic syndromes. Clin Cancer Res. 21:3541–3551. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tang JL, Hou HA, Chen CY, Liu CY, Chou WC,
Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, et al: AML1/RUNX1
mutations in 470 adult patients with de novo acute myeloid
leukemia: Prognostic implication and interaction with other gene
alterations. Blood. 114:5352–5361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dicker F, Haferlach C, Sundermann J,
Wendland N, Weiss T, Kern W, Haferlach T and Schnittger S: Mutation
analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269
patients with MDS or secondary AML. Leukemia. 24:1528–1532. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Savage KI, Gorski JJ, Barros EM, Irwin GW,
Manti L, Powell AJ, Pellagatti A, Lukashchuk N, McCance DJ,
McCluggage WG, et al: Identification of a BRCA1-mRNA splicing
complex required for efficient DNA repair and maintenance of
genomic stability. Mol Cell. 54:445–459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dalton WB, Helmenstine E, Walsh N, Gondek
LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S,
et al: Hotspot SF3B1 mutations induce metabolic reprogramming and
vulnerability to serine deprivation. J Clin Invest. 129:4708–4723.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Papaemmanuil E, Cazzola M, Boultwood J,
Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS,
Hellstrom-Lindberg E, Gambacorti-Passerini C, et al: Somatic SF3B1
mutation in myelodysplasia with ring sideroblasts. N Engl J Med.
365:1384–1395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yoshida K, Sanada M, Shiraishi Y, Nowak D,
Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, et
al: Frequent pathway mutations of splicing machinery in
myelodysplasia. Nature. 478:64–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Malcovati L, Stevenson K, Papaemmanuil E,
Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL,
Fenaux P, et al: SF3B1-mutant MDS as a distinct disease subtype: A
proposal from the international working group for the prognosis of
MDS. Blood. 136:157–170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Itzykson R, Kosmider O, Renneville A,
Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L,
Fenaux P, Beyne-Rauzy O, et al: Prognostic score including gene
mutations in chronic myelomonocytic leukemia. J Clin Oncol.
31:2428–2436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ganguly BB and Kadam NN: Mutations of
myelodysplastic syndromes (MDS): An update. Mutat Res Rev Mutat
Res. 769:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Thol F, Kade S, Schlarmann C, Löffeld P,
Morgan M, Krauter J, Wlodarski MW, Kölking B, Wichmann M, Görlich
K, et al: Frequency and prognostic impact of mutations in SRSF2,
U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood.
119:3578–3584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Makishima H, Visconte V, Sakaguchi H,
Jankowska AM, Kar SA, Jerez A, Przychodzen B, Bupathi M, Guinta K,
Afable MG, et al: Mutations in the spliceosome machinery, a novel
and ubiquitous pathway in leukemogenesis. Blood. 119:3203–3210.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Harada H and Harada Y: Recent advances in
myelodysplastic syndromes: Molecular pathogenesis and its
implications for targeted therapies. Cancer Sci. 106:329–336. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wu SJ, Tang JL, Lin CT, Kuo YY, Li LY,
Tseng MH, Huang CF, Lai YJ, Lee FY, Liu MC, et al: Clinical
implications of U2AF1 mutation in patients with myelodysplastic
syndrome and its stability during disease progression. Am J
Hematol. 88:E277–E282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Park SM, Ou J, Chamberlain L, Simone TM,
Yang H, Virbasius CM, Ali AM, Zhu LJ, Mukherjee S, Raza A and Green
MR: U2AF35(S34F) promotes transformation by directing aberrant ATG7
Pre-mRNA 3′ end formation. Mol Cell. 62:479–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Smith MA, Choudhary GS, Pellagatti A, Choi
K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan
K, Steeples V, et al: U2AF1 mutations induce oncogenic IRAK4
isoforms and activate innate immune pathways in myeloid
malignancies. Nat Cell Biol. 21:640–650. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shirai CL, White BS, Tripathi M, Tapia R,
Ley JN, Ndonwi M, Kim S, Shao J, Carver A, Saez B, et al: Mutant
U2AF1-expressing cells are sensitive to pharmacological modulation
of the spliceosome. Nat Commun. 8:140602017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Raddatz G, Gao Q, Bender S, Jaenisch R and
Lyko F: Dnmt3a protects active chromosome domains against
cancer-associated hypomethylation. PLoS Genet. 8:e10031462012.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ley TJ, Ding L, Walter MJ, McLellan MD,
Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et
al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med.
363:2424–2433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Thol F, Winschel C, Lüdeking A, Yun H,
Friesen I, Damm F, Wagner K, Krauter J, Heuser M and Ganser A: Rare
occurrence of DNMT3A mutations in myelodysplastic syndromes.
Haematologica. 96:1870–1873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ko M, Huang Y, Jankowska AM, Pape UJ,
Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R,
et al: Impaired hydroxylation of 5-methylcytosine in myeloid
cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Moran-Crusio K, Reavie L, Shih A,
Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar
A, Patel J, Zhao X, et al: Tet2 loss leads to increased
hematopoietic stem cell self-renewal and myeloid transformation.
Cancer Cell. 20:11–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Seethy AA, Pethusamy K, Kushwaha T, Kumar
G, Talukdar J, Chaubey R, Sundaram UD, Mahapatra M, Saxena R, Dhar
R, et al: Alterations of the expression of TET2 and DNA 5-hmC
predict poor prognosis in myelodysplastic neoplasms. BMC Cancer.
23:10352023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS,
Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et
al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell. 18:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Thol F, Weissinger EM, Krauter J, Wagner
K, Damm F, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, et
al: IDH1 mutations in patients with myelodysplastic syndromes are
associated with an unfavorable prognosis. Haematologica.
95:1668–1674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zarnegar-Lumley S, Alonzo TA, Gerbing RB,
Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F,
et al: Characteristics and prognostic impact of IDH mutations in
AML: A COG, SWOG, and ECOG analysis. Blood Adv. 7:5941–5953. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Jaiswal S and Ebert BL: Clonal
hematopoiesis in human aging and disease. Science.
366:eaan46732019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Mohrin M, Bourke E, Alexander D, Warr MR,
Barry-Holson K, Le Beau MM, Morrison CG and Passegué E:
Hematopoietic stem cell quiescence promotes error-prone DNA repair
and mutagenesis. Cell Stem Cell. 7:174–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Medina EA, Delma CR and Yang FC: ASXL1/2
mutations and myeloid malignancies. J Hematol Oncol. 15:1272022.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Issa JP: Epigenetic changes in the
myelodysplastic syndrome. Hematol Oncol Clin North Am. 24:317–330.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Claus R and Lübbert M: Epigenetic targets
in hematopoietic malignancies. Oncogene. 22:6489–6496. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Brakensiek K, Länger F, Schlegelberger B,
Kreipe H and Lehmann U: Hypermethylation of the suppressor of
cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J
Haematol. 130:209–217. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Christiansen DH, Andersen MK and
Pedersen-Bjergaard J: Methylation of p15INK4B is common, is
associated with deletion of genes on chromosome arm 7q and predicts
a poor prognosis in therapy-related myelodysplasia and acute
myeloid leukemia. Leukemia. 17:1813–1819. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Stintzing S, Kemmerling R, Kiesslich T,
Alinger B, Ocker M and Neureiter D: Myelodysplastic syndrome and
histone deacetylase inhibitors: ‘To be or not to be acetylated’? J
Biomed Biotechnol. 2011:2141432011.PubMed/NCBI
|
|
88
|
Gill H, Leung AY and Kwong YL: Molecular
and cellular mechanisms of myelodysplastic syndrome: Implications
on targeted therapy. Int J Mol Sci. 17:4402016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chen D, Xia S, Zhang R, Li Y, Famulare CA,
Fan H, Wu R, Wang M, Zhu AC, Elf SE, et al: Lysine acetylation
restricts mutant IDH2 activity to optimize transformation in AML
cells. Mol Cell. 81:3833–3847.e3811. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sundaravel S, Duggan R, Bhagat T, Ebenezer
DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC,
et al: Reduced DOCK4 expression leads to erythroid dysplasia in
myelodysplastic syndromes. Proc Natl Acad Sci USA. 112:E6359–E6368.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
O'Connell RM, Chaudhuri AA, Rao DS, Gibson
WS, Balazs AB and Baltimore D: MicroRNAs enriched in hematopoietic
stem cells differentially regulate long-term hematopoietic output.
Proc Natl Acad Sci USA. 107:14235–14240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wen J, Huang Y, Li H, Zhang X, Cheng P,
Deng D, Peng Z, Luo J, Zhao W, Lai Y and Liu Z: Over-expression of
miR-196b-5p is significantly associated with the progression of
myelodysplastic syndrome. Int J Hematol. 105:777–783. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Miller PG, Al-Shahrour F, Hartwell KA, Chu
LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey
ME, et al: In vivo RNAi screening identifies a leukemia-specific
dependence on integrin beta 3 signaling. Cancer Cell. 24:45–58.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Burger JA and Peled A: CXCR4 antagonists:
Targeting the microenvironment in leukemia and other cancers.
Leukemia. 23:43–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Dührsen U and Hossfeld DK: Stromal
abnormalities in neoplastic bone marrow diseases. Ann Hematol.
73:53–70. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Behrmann L, Wellbrock J and Fiedler W:
Acute myeloid leukemia and the bone marrow niche-take a closer
look. Front Oncol. 8:4442018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sha C, Jia G, Jingjing Z, Yapeng H, Zhi L
and Guanghui X: miR-486 is involved in the pathogenesis of acute
myeloid leukemia by regulating JAK-STAT signaling. Naunyn
Schmiedebergs Arch Pharmacol. 394:177–187. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Fattizzo B, Giannotta JA and Barcellini W:
Mesenchymal stem cells in aplastic anemia and myelodysplastic
syndromes: The ‘Seed and Soil’ crosstalk. Int J Mol Sci.
21:54382020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Bhagat TD, Chen S, Bartenstein M, Barlowe
AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM,
Sanders MA, et al: Epigenetically aberrant stroma in MDS propagates
disease via Wnt/β-catenin activation. Cancer Res. 77:4846–4857.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Kode A, Manavalan JS, Mosialou I, Bhagat
G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R,
et al: Leukaemogenesis induced by an activating β-catenin mutation
in osteoblasts. Nature. 506:240–244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kuek V, Hughes AM, Kotecha RS and Cheung
LC: Therapeutic targeting of the leukaemia microenvironment. Int J
Mol Sci. 22:68882021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Fiedler W, Graeven U, Ergün S, Verago S,
Kilic N, Stockschläder M and Hossfeld DK: Vascular endothelial
growth factor, a possible paracrine growth factor in human acute
myeloid leukemia. Blood. 89:1870–1875. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cancilla D, Rettig MP and DiPersio JF:
Targeting CXCR4 in AML and ALL. Front Oncol. 10:16722020.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Barbier V, Erbani J, Fiveash C, Davies JM,
Tay J, Tallack MR, Lowe J, Magnani JL, Pattabiraman DR, Perkins AC,
et al: Endothelial E-selectin inhibition improves acute myeloid
leukaemia therapy by disrupting vascular niche-mediated
chemoresistance. Nat Commun. 11:20422020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Kotsianidis I, Bouchliou I, Nakou E,
Spanoudakis E, Margaritis D, Christophoridou AV, Anastasiades A,
Tsigalou C, Bourikas G, Karadimitris A and Tsatalas C: Kinetics,
function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory
T cells in myelodysplastic syndromes (MDS). Leukemia. 23:510–518.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Tay C, Tanaka A and Sakaguchi S:
Tumor-infiltrating regulatory T cells as targets of cancer
immunotherapy. Cancer Cell. 41:450–465. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ehrchen JM, Sunderkötter C, Foell D, Vogl
T and Roth J: The endogenous toll-like receptor 4 agonist
S100A8/S100A9 (calprotectin) as innate amplifier of infection,
autoimmunity, and cancer. J Leukoc Biol. 86:557–566. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Gañán-Gómez I, Wei Y, Starczynowski DT,
Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U
and Garcia-Manero G: Deregulation of innate immune and inflammatory
signaling in myelodysplastic syndromes. Leukemia. 29:1458–1469.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Schütz F, Stefanovic S, Mayer L, von Au A,
Domschke C and Sohn C: PD-1/PD-L1 pathway in breast cancer. Oncol
Res Treat. 40:294–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Garris CS, Arlauckas SP, Kohler RH, Trefny
MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M,
Gungabeesoon J, et al: Successful anti-PD-1 cancer immunotherapy
requires T cell-dendritic cell crosstalk involving the cytokines
IFN-γ and IL-12. Immunity. 49:1148–1161.e1147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
114
|
Woan KV and Miller JS: Harnessing natural
killer cell antitumor immunity: From the bench to bedside. Cancer
Immunol Res. 7:1742–1747. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Scoville SD, Nalin AP, Chen L, Chen L,
Zhang MH, McConnell K, Casas SB, Ernst G, Traboulsi AA, Hashi N, et
al: Human AML activates the aryl hydrocarbon receptor pathway to
impair NK cell development and function. Blood. 132:1792–1804.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Janowska-Wieczorek A, Marquez-Curtis LA,
Gan K, Larratt L and Woods A: TNF-α stimulates matrix
metalloproteinase expression in myelodysplastic syndromes (MDS)::
Therapeutic potential for inhibitors of TNF-α and MMPs. Blood.
106:962A. 2005. View Article : Google Scholar
|
|
117
|
Bruno S, Mancini M, De Santis S, Monaldi
C, Cavo M and Soverini S: The role of hypoxic bone marrow
microenvironment in acute myeloid leukemia and future therapeutic
opportunities. Int J Mol Sci. 22:68572021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Chiarini F, Lonetti A, Evangelisti C,
Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM,
McCubrey JA and Martelli AM: Advances in understanding the acute
lymphoblastic leukemia bone marrow microenvironment: From biology
to therapeutic targeting. Biochim Biophys Acta. 1863:449–463. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Heiden MG, Cantley LC and Thompson CB:
Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Clem B, Telang S, Clem A, Yalcin A, Meier
J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, et al:
Small-molecule inhibition of 6-phosphofructo-2-kinase activity
suppresses glycolytic flux and tumor growth. Mol Cancer Ther.
7:110–120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang L, Yang L, Yang Z, Tang Y, Tao Y,
Zhan Q, Lei L, Jing Y, Jiang X, Jin H, et al: Glycolytic enzyme
PKM2 mediates autophagic activation to promote cell survival in
NPM1-mutated leukemia. Int J Biol Sci. 15:882–894. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Dunn WG, McLoughlin MA and Vassiliou GS:
Clonal hematopoiesis and hematological malignancy. J Clin Invest.
134:e1800652024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Bowman RL, Busque L and Levine RL: Clonal
hematopoiesis and evolution to hematopoietic malignancies. Cell
Stem Cell. 22:157–170. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wilkinson AC, Morita M, Nakauchi H and
Yamazaki S: Branched-chain amino acid depletion conditions bone
marrow for hematopoietic stem cell transplantation avoiding amino
acid imbalance-associated toxicity. Exp Hematol. 63:12–16.e11.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Raffel S, Falcone M, Kneisel N, Hansson J,
Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A,
et al: BCAT1 restricts αKG levels in AML stem cells leading to
IDHmut-like DNA hypermethylation. Nature. 551:384–388. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Walter MJ, Shen D, Shao J, Ding L, White
BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, et al:
Clonal diversity of recurrently mutated genes in myelodysplastic
syndromes. Leukemia. 27:1275–1282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Mortera-Blanco T, Dimitriou M, Woll PS,
Karimi M, Elvarsdottir E, Conte S, Tobiasson M, Jansson M, Douagi
I, Moarii M, et al: SF3B1-initiating mutations in MDS-RSs target
lymphomyeloid hematopoietic stem cells. Blood. 130:881–890. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Makishima H, Yoshizato T, Yoshida K,
Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y,
Meggendorfer M, Sanada M, et al: Dynamics of clonal evolution in
myelodysplastic syndromes. Nat Genet. 49:204–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Seymour JF, Döhner H, Butrym A,
Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC,
Candoni A, et al: Azacitidine improves clinical outcomes in older
patients with acute myeloid leukaemia with myelodysplasia-related
changes compared with conventional care regimens. BMC Cancer.
17:8522017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Abdallah M, Xie Z, Ready A, Manogna D,
Mendler JH and Loh KP: Management of acute myeloid leukemia (AML)
in older patients. Curr Oncol Rep. 22:1032020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
LeBlanc TW and Erba HP: Shifting paradigms
in the treatment of older adults with AML. Semin Hematol.
56:110–117. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kronfol MM, Jahr FM, Dozmorov MG,
Phansalkar PS, Xie LY, Aberg KA, McRae M, Price ET, Slattum PW,
Gerk PM and McClay JL: DNA methylation and histone acetylation
changes to cytochrome P450 2E1 regulation in normal aging and
impact on rates of drug metabolism in the liver. Geroscience.
42:819–832. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bose P and Grant S: Rational combinations
of targeted agents in AML. J Clin Med. 4:634–664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sotiropoulou IM, Manetas-Stavrakakis N,
Kourek C, Xanthopoulos A, Magouliotis D, Giamouzis G, Skoularigis J
and Briasoulis A: Prevention of anthracyclines and HER2
inhibitor-induced cardiotoxicity: A systematic review and
meta-analysis. Cancers (Basel). 16:24192024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Doval D, Sharma SK, Kumar M, Khandelwal V
and Choudhary D: Cytarabine ears-A side effect of cytarabine
therapy. J Oncol Pharm Pract. 26:471–473. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Gardin C, Pautas C, Fournier E, Itzykson
R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV,
Gastaud L, et al: Added prognostic value of secondary AML-like gene
mutations in ELN intermediate-risk older AML: ALFA-1200 study
results. Blood Adv. 4:1942–1949. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Russell NH: Improving outcomes for elderly
patients with AML. Lancet Oncol. 13:1065–1066. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Brandwein JM, Geddes M, Kassis J, Kew AK,
Leber B, Nevill T, Sabloff M, Sandhu I, Schuh AC, Storring JM and
Ashkenas J: Treatment of older patients with acute myeloid leukemia
(AML): A Canadian consensus. Am J Blood Res. 3:141–164.
2013.PubMed/NCBI
|
|
139
|
Zhao D, Zarif M, Eladl E, Capo-Chichi JM,
Smith AC, Atenafu EG, Tierens A, Minden MD, Schuh A and Chang H:
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or
MDS/MPN frequently harbours secondary-type mutations and confers
inferior outcome compared to AML with mutated NPM1. Leuk Res.
118:1068692022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Cruijsen M, Lübbert M, Wijermans P and
Huls G: Clinical Results of Hypomethylating agents in AML
treatment. J Clin Med. 4:1–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Stomper J and Lübbert M: Can we predict
responsiveness to hypomethylating agents in AML? Semin Hematol.
56:118–124. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Sadeghi M, Khodakarami A, Ahmadi A,
Navashenaq JG, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Akbari AA
and Jadidi-Niaragh F: The prognostic and therapeutic potentials of
CTLA-4 in hematological malignancies. Expert Opin Ther Targets.
26:1057–1071. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Tan J, Yu Z, Huang J, Chen Y, Huang S, Yao
D, Xu L, Lu Y, Chen S and Li Y: Increased PD-1+Tim-3+ exhausted T
cells in bone marrow may influence the clinical outcome of patients
with AML. Biomark Res. 8:62020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wang D, Zhou F, He L, Wang X, Song L, Wang
H, Sun S, Guo Z, Ma K, Xu J and Cui C: AML cell-derived exosomes
suppress the activation and cytotoxicity of NK cells in AML via
PD-1/PD-L1 pathway. Cell Biol Int. 48:1588–1598. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Hwang HS, Han AR, Lee JY, Park GS, Min WS
and Kim HJ: Enhanced anti-leukemic effects through induction of
immunomodulating microenvironment by blocking CXCR4 and PD-L1 in an
AML mouse model. Immunol Invest. 48:96–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kotsiafti A, Giannakas K, Christoforou P
and Liapis K: Progress toward better treatment of therapy-related
AML. Cancers (Basel). 15:16582023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Yin JA, O'Brien MA, Hills RK, Daly SB,
Wheatley K and Burnett AK: Minimal residual disease monitoring by
quantitative RT-PCR in core binding factor AML allows risk
stratification and predicts relapse: Results of the United Kingdom
MRC AML-15 trial. Blood. 120:2826–2835. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Canaani J: Management of AML beyond ‘3 +
7’ in 2019. Clin Hematol Int. 1:10–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Alfayez M, Kantarjian H, Kadia T,
Ravandi-Kashani F and Daver N: CPX-351 (vyxeos) in AML. Leuk
Lymphoma. 61:288–297. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
National Comprehensive Cancer Network
(NCCN), . NCCN Guidelines Version 2.2024: Acute myeloid leukemia.
NCCN; Plymouth Meeting, PA: 2024
|
|
151
|
Lancet JE, Uy GL, Cortes JE, Newell LF,
Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR,
et al: CPX-351 (cytarabine and daunorubicin) liposome for injection
versus conventional cytarabine plus daunorubicin in older patients
with newly diagnosed secondary acute myeloid leukemia. J Clin
Oncol. 36:2684–2692. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Krauss AC, Gao X, Li L, Manning ML, Patel
P, Fu W, Janoria KG, Gieser G, Bateman DA, Przepiorka D, et al: FDA
approval summary: (Daunorubicin and Cytarabine) liposome for
injection for the treatment of adults with high-risk acute myeloid
leukemia. Clin Cancer Res. 25:2685–2690. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wang Q, Tardi P, Sadowski N, Xie S, Heller
D and Mayer L: Pharmacokinetics, drug metabolism, and tissue
distribution of CPX-351 in animals. Nanomedicine. 30:1022752020.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chiche E, Rahmé R, Bertoli S, Dumas PY,
Micol JB, Hicheri Y, Pasquier F, Peterlin P, Chevallier P and
Thomas X: Real-life experience with CPX-351 and impact on the
outcome of high-risk AML patients: A multicentric French cohort.
Blood Adv. 5:176–184. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Tolcher AW and Mayer LD: Improving
combination cancer therapy: The CombiPlex® development
platform. Future Oncol. 14:1317–1332. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Hellström-Lindberg ES and Kröger N:
Clinical decision-making and treatment of myelodysplastic
syndromes. Blood. 142:2268–2281. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Koenig KL, Sahasrabudhe KD, Sigmund AM and
Bhatnagar B: AML with myelodysplasia-related changes: Development,
challenges, and treatment advances. Genes (Basel). 11:8452020.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Dombret H, Seymour JF, Butrym A,
Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC,
Candoni A, et al: International phase 3 study of azacitidine vs
conventional care regimens in older patients with newly diagnosed
AML with >30% blasts. Blood. 126:291–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH,
Huang XJ and Jiang H: Efficacy and safety of decitabine in
combination with G-CSF, low-dose cytarabine and aclarubicin in
MDS-EB and AML-MRC. Zhonghua Xue Ye Xue Za Zhi. 39:734–738.
2018.(In Chinese). PubMed/NCBI
|
|
160
|
Assi R, Kantarjian H, Ravandi F and Daver
N: Immune therapies in acute myeloid leukemia: A focus on
monoclonal antibodies and immune checkpoint inhibitors. Curr Opin
Hematol. 25:136–145. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Yuan XL, Wu YB, Song XL, Chen Y, Lu Y, Lai
XY, Shi JM, Liu LZ, Zhao YM, Yu J, et al: Efficacy and prognostic
factors of allogeneic hematopoietic stem cell transplantation in
the treatment of secondary acute myeloid leukemia. Zhonghua Xue Ye
Xue Za Zhi. 45:41–47. 2024.PubMed/NCBI
|
|
162
|
Pan R, Hogdal LJ, Benito JM, Bucci D, Han
L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, et al:
Selective BCL-2 inhibition by ABT-199 causes on-target cell death
in acute myeloid leukemia. Cancer Discov. 4:362–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
DiNardo CD, Jonas BA, Pullarkat V, Thirman
MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, et
al: Azacitidine and venetoclax in previously untreated acute
myeloid leukemia. N Engl J Med. 383:617–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Waclawiczek A, Leppä AM, Renders S, Stumpf
K, Reyneri C, Betz B, Janssen M, Shahswar R, Donato E, Karpova D,
et al: Combinatorial bcl2 family expression in acute myeloid
leukemia stem cells predicts clinical response to
Azacitidine/Venetoclax. Cancer Discov. 13:1408–1427. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Wan CL, Liu YQ, Liu FT, Huang YH, Cao HY,
Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, et al: Venetoclax with
hypomethylating agents versus intensive chemotherapy in newly
diagnosed acute myeloid leukemia with myelodysplasia related
changes: A propensity score-matched analysis based on international
consensus classification. Blood Cancer J. 14:1442024. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Fiskus W, Sharma S, Shah B, Portier BP,
Devaraj SGT, Liu K, Iyer SP, Bearss D and Bhalla KN: Highly
effective combination of LSD1 (KDM1A) antagonist and pan-histone
deacetylase inhibitor against human AML cells. Leukemia.
28:2155–2164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Sugino N, Kawahara M, Tatsumi G, Kanai A,
Matsui H, Yamamoto R, Nagai Y, Fujii S, Shimazu Y, Hishizawa M, et
al: A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia
with complex karyotype by attenuating leukemia programs via
activating super-enhancers. Leukemia. 31:2303–2314. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
List A, Dewald G, Bennett J, Giagounidis
A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, et
al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q
deletion. N Engl J Med. 355:1456–1465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
List A, Kurtin S, Roe DJ, Buresh A,
Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R and Zeldis JB:
Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J
Med. 352:549–557. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Nimer SD: Clinical management of
myelodysplastic syndromes with interstitial deletion of chromosome
5q. J Clin Oncol. 24:2576–2582. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Brune MM, Stüssi G, Lundberg P, Vela V,
Heim D, Manz MG, Haralambieva E, Pabst T, Banz Y, Bargetzi M, et
al: Effects of lenalidomide on the bone marrow microenvironment in
acute myeloid leukemia: Translational analysis of the HOVON103
AML/SAKK30/10 Swiss trial cohort. Ann Hematol. 100:1169–1179. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Daver N, Konopleva M, Maiti A, Kadia TM,
DiNardo CD, Loghavi S, Pemmaraju N, Jabbour EJ, Montalban-Bravo G,
Tang G, et al: Phase I/II study of azacitidine (AZA) with
venetoclax (VEN) and magrolimab (Magro) in patients (pts) with
newly diagnosed older/unfit or high-risk acute myeloid leukemia
(AML) and relapsed/refractory (R/R) AML. Blood. 138:371–374. 2021.
View Article : Google Scholar
|
